中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (2): 145-148.
孙洁,龚春燕
收稿日期:2016-05-13
修回日期:2016-05-31
出版日期:2017-02-15
发布日期:2017-01-24
通讯作者:
龚春燕
E-mail:13057687408@163.com
Jie SUN1,Chun-Yan GONG
Received:2016-05-13
Revised:2016-05-31
Online:2017-02-15
Published:2017-01-24
Contact:
Chun-Yan GONG
E-mail:13057687408@163.com
摘要： 银屑病是一种慢性炎症性皮肤疾病，斑块状银屑病是最常见的类型，约占80%［1］。7% ~ 40%的银屑病患者会发展成关节病性银屑病［2］。传统治疗银屑病的药物包括甲氨蝶呤、环孢素、阿维A等，治疗银屑病关节炎的药物包括甲氨蝶呤、柳氮磺吡啶、来氟米特等，它们各有不同程度的疗效，但不良反应也多。同时，患有严重银屑病和关节病性银屑病的患者多数有各种合并症［3］，如代谢综合征、缺血性心脏病和非酒精性脂肪肝等，这也限制了治疗药物的选择范围。近10年，生物制剂不断发展，肿瘤坏死因子α（TNF?α）抑制剂、白细胞介素17（IL?17）抑制剂等的有效性和安全性均高于传统药物，但持续静脉给药的方式和昂贵的价格降低患者的依从性。另外，生物制剂的疗效会由于中和抗体的产生而下降［4］。阿普斯特是一种口服的小分子磷酸二酯酶4（PDE4）抑制剂，2014年已被美国食品药品监督管理局（FDA）和EMA（European Medicines Agency）批准治疗银屑病和关节病性银屑病……
孙洁 龚春燕. 治疗斑块状银屑病和银屑病关节炎的新药——阿普斯特[J]. 中华皮肤科杂志, 2017, 50(2): 145-148.
Jie SUN Chun-Yan GONG. Apremilast: a novel drug for the treatment of plaque psoriasis and psoriatic arthritis[J]. Chinese Journal of Dermatology, 2017, 50(2): 145-148.
| ［1］ | Boehncke WH, Schön MP. Psoriasis［J］. Lancet, 2015, 386（9997）: 983⁃994. DOI: 10.1016/S0140⁃6736（14）61909⁃7. |
| ［2］ | 吴华香, 李军, 郑敏. 银屑病关节炎的临床特征和治疗［J］. 中华皮肤科杂志, 2005, 38（3）: 170⁃171. DOI: 10.3760/j.issn:0412⁃4030.2005.03.013. |
| ［3］ | Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis［J］. Lancet, 2007, 370（9583）: 263⁃271. DOI: 10.1016/S0140⁃6736（07）61128⁃3. |
| ［4］ | Aslam A, Griffiths CE. Drug therapies in dermatology［J］. Clin Med （Lond）, 2014, 14（1）: 47⁃53. DOI: 10.7861/clinmedicine.14⁃1⁃47. |
| ［5］ | Ahmad F, Murata T, Shimizu K, et al. Cyclic nucleotide phospho⁃diesterases: important signaling modulators and therapeutic targets［J］. Oral Dis, 2015, 21（1）: e25⁃50. DOI: 10.1111/odi.12275. |
| ［6］ | Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis［J］. Curr Rheumatol Rep, 2014, 16（9）: 443. DOI: 10.1007/s11926⁃014⁃0443⁃6. |
| ［7］ | Martin TJ. PDE4 inhibitors ⁃ a review of the recent patent literature［J］. IDrugs, 2001, 4（3）: 312⁃338. |
| ［8］ | Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase⁃4 inhibitor, demonstrates anti⁃inflammatory activity in vitro and in a model of psoriasis［J］. Br J Pharmacol, 2010, 159（4）: 842⁃855. DOI: 10.1111/j.1476⁃5381.2009.00559.x. |
| ［9］ | Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase Ⅲ, randomized, placebo⁃controlled trial （PALACE 1）［J］. J Immunol Res, 2015, 2015: 906349. DOI: 10.1155/2015/906349. |
| ［10］ | Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity［J］. Cell Signal, 2014, 26（9）: 2016⁃2029. DOI: 10.1016/j.cellsig.2014. 05.014. |
| ［11］ | Otezla （apremilast） prescribing information［DB/OL］. December 2014. http://www.otezla.com/otezla⁃prescribing⁃information.pdf. |
| ［12］ | Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial［J］. Lancet, 2012, 380（9843）: 738⁃746. DOI: 10.1016/S0140⁃6736（12）60642⁃4. |
| ［13］ | Strand V, Fiorentino D, Hu C, et al. Improvements in patient⁃reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase Ⅱb randomized, controlled study［J］. Health Qual Life Outcomes, 2013, 11： 82. DOI: 10.1186/1477⁃7525⁃11⁃82. |
| ［14］ | Papp KA, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase Ⅱ, multicenter, randomized, double⁃blind, placebo⁃controlled, parallel⁃group, dose⁃comparison study［J］. J Eur Acad Dermatol Venereol, 2013, 27（3）: e376⁃383. DOI: 10.1111/j.1468⁃3083.2012.04716.x. |
| ［15］ | Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase Ⅲ, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015, 73（1）: 37⁃49. DOI: 10.1016/j.jaad.2015.03.049. |
| ［16］ | Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase Ⅲ, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015, 173（6）: 1387⁃1399. DOI: 10.1111/bjd.14164. |
| ［17］ | Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phase Ⅲ randomized, controlled trials （ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016, 74（1）: 134⁃142. DOI: 10.1016/j.jaad.2015.09. 001. |
| ［18］ | Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double⁃blind, placebo⁃controlled study［J］. Arthritis Rheum, 2012, 64（10）: 3156⁃3167. DOI: 10.1002/art.34627. |
| ［19］ | Strand V, Schett G, Hu C, et al. Patient⁃reported Health⁃related Quality of Life with apremilast for psoriatic arthritis: a phase Ⅱ, randomized, controlled study［J］. J Rheumatol, 2013, 40（7）: 1158⁃1165. DOI: 10.3899/jrheum.121200. |
| ［20］ | Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo⁃controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor［J］. Ann Rheum Dis, 2014, 73（6）: 1020⁃1026. DOI: 10.1136/annrheumdis⁃2013⁃205056. |
| ［21］ | Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Longterm （52⁃week） results of a phase Ⅲ randomized, controlled trial of apremilast in patients with psoriatic arthritis［J］. J Rheumatol, 2015, 42（3）: 479⁃488. DOI: 10.3899/jrheum.140647. |
| ［22］ | Kavanaugh A, Adebajo A, Gladman D, et al. Long⁃term （104⁃week） efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results from a phase Ⅲ, randomized, controlled trial and open⁃label extension （PALACE 1）［C/OL］//70th Annual Meeting of the Canadian Rheumatology Association, Quebec City, QC Canada, 2015. Canada: J Rheumatol, 2015, 42（7）. |
| ［23］ | Kavanaugh A, Gladman DD, Gomez⁃Reino JJ, et al. Long⁃term （156⁃week） efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results from a phase Ⅲ, randomized, controlled trial and open⁃label extension （PALACE 1）［J］. Arthritis Rheumatol, 2015, 72（5 Suppl 1）: AB227. |
| ［24］ | Cutolo M, Myerson GE, Fleischmann RM, et al. Long⁃term （52⁃week） results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis （PALACE 2）［C/OL］//ACR/ARHP Annual Meeting, San Diego, 2013. |
| ［25］ | Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase Ⅲ, randomised, controlled trial （PALACE 3）［J］. Ann Rheum Dis, 2016, 75（6）: 1065⁃1073. DOI: 10.1136/annrheumdis⁃2015⁃207963. |
| ［26］ | Edwards CJ, Wells AF, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long⁃term （52⁃Week） improvements in enthesitis or dactylitis in patients with psoriatic arthritis: results from the PALACE 4 phase 3, randomized, controlled trial. Annual European Congress of Rheumatology （EULAR）, Paris, 2014［J］. Paris: Ann Rheum Dis, 2014, 73: 735. DOI: 10.1136/annrheumdis⁃2014⁃eular.1574. |
| ［27］ | Mease P, Gladman D, Kavanaugh A, et al. Change in weight from baseline during the Palace Clinical Trial Program with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 phase 3, randomized, controlled trials［J］. Ann Rheum Dis, 2014, 73（Suppl 2）: 1055. DOI: 10.1136/annrheumdis⁃2014⁃eular.2391. |
| ［28］ | Menter A, Paul C, Stevens RM, et al. Psychiatric disorders and depression incidence with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials［C/OL］//23rd Congress of the European Academy of Dermatology and Venereology, Amsterdam, 2014. |
| ［29］ | Papp KA, Reich K, Sobell JM, et al. Two⁃year safety of apremi⁃last, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results from a phase 3, randomized, controlled trial （ESTEEM 1）［J］. J Am Acad Dermatol, 2015, 72（5 Suppl 1）: AB256. |
| ［30］ | Kurd SK, Troxel AB, Crits⁃Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population⁃based cohort study［J］. Arch Dermatol, 2010, 146（8）: 891⁃895. DOI: 10.1001/archdermatol.2010.186. |
| ［31］ | Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009⁃2012［J］. JAMA Dermatol, 2016, 152（1）: 73⁃79. DOI: 10.1001/jamadermatol.2015.3605. |
| ［32］ | Feldam SR, Tencer T, Clancy Z, et al. Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis［C/OL］//73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA, 2015. |
| ［33］ | Liu Y, Zhou S, Nissel J, et al. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis［J］. Clin Pharmacol Drug Dev, 2014, 3（6）: 456⁃465. DOI: 10.1002/cpdd.109. |
| ［34］ | Danesh MJ, Beroukhim K, Nguyen C, et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis［J/OL］. Dermatol Online J, 2015, 21（6）［2016⁃03⁃20］. http://escholarship.org/uc/item/5gf406zs. |
| [1] | 陈怡雯 苏婷 苏忠兰. 银屑病与STAT3[J]. 中华皮肤科杂志, 2019, 52(7): 502-505. |
| [2] | 苏蓓蓓 甘泉 甘才斌. 二甲双胍对银屑病样小鼠模型皮损炎症状态及磷酸化Stat3蛋白表达的影响[J]. 中华皮肤科杂志, 2019, 52(7): 475-480. |
| [3] | 覃慧 郑捷. 鞘氨醇1-磷酸盐受体拮抗剂（FTY720）抑制皮肤中分泌白细胞介素17的γδT细胞治疗银屑病的机制研究[J]. 中华皮肤科杂志, 2019, 52(6): 395-400. |
| [4] | 王丽玮 罗玲玲 崔盘根 李岷. 肠道菌群与银屑病关系的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 357-360. |
| [5] | 胡煜 陈敏 顾恒. microRNA和lncRNA在银屑病中的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 350-353. |
| [6] | 潘家旭 周婧. 核因子κB信号通路在银屑病中的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 361-363. |
| [7] | 曾菁莘 田歆 朱慧兰 张锡宝 林玲 张丽丹 刘炜钰 罗权. 微小RNA-148a-3p在寻常型银屑病患者外周血CD4+ T淋巴细胞中的表达及临床意义[J]. 中华皮肤科杂志, 2019, 52(4): 231-235. |
| [8] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018简版）[J]. 中华皮肤科杂志, 2019, 52(4): 223-230. |
| [9] | 中国医师协会皮肤科医师分会规范化诊疗工作委员会 中国医学装备协会皮肤病与皮肤美容专业委员会皮肤外科装备学组和皮肤光治疗学组. 窄谱中波紫外线家庭光疗临床应用专家共识[J]. 中华皮肤科杂志, 2019, 52(3): 156-161. |
| [10] | 高祎濛 晋红中. 精神神经因素在银屑病发病中的作用[J]. 中华皮肤科杂志, 2019, 52(3): 204-207. |
| [11] | 关欣 张春雷. 英夫利西单抗长疗程治疗中重度寻常性银屑病的疗效评价[J]. 中华皮肤科杂志, 2019, 52(2): 86-89. |
| [12] | 彭琛 陈文娟 于宁 高芸璐 易雪梅 丁杨峰. 银屑病皮肤及肠道微生态研究进展[J]. 中华皮肤科杂志, 2019, 52(2): 135-137. |
| [13] | 王刚. 皮肤科生物制剂的主要不良反应及对策[J]. 中华皮肤科杂志, 2019, 52(2): 77-80. |
| [14] | 胡煜 栾超 练霓 郝志敏 孙玉洁 王焱 顾恒 陈敏. 银屑病患者血浆中前蛋白转化酶枯草溶菌素9的表达及对外周血CD4+ T细胞活化的影响[J]. 中华皮肤科杂志, 2019, 52(2): 90-93. |
| [15] | 熊娟娟 毕健平 孙德祥 李念 鲁巧云. 甲真菌病和甲银屑病的皮肤镜特征分析[J]. 中华皮肤科杂志, 2019, 52(2): 106-110. |
|
